ASPR/BARDA has issued a Request for Information (RFI) to assist in understanding the developmental landscape of next generation blood products that could be used to treat mechanical trauma and bleeding associated with acute radiation syndrome and potentially supplement the blood supply in the wake of a mass casualty event such as a nuclear or radiological scenario.
The focus of this RFI is the identification of next generation blood products or analogous technologies with improved storage characteristics, allowing these products to be stockpiled or pre-deployed and in routine use either in a hospital or pre-hospital setting. Universal products that eliminate the need for donor/recipient compatibility testing will also be a major benefit.
BARDA intends to use responses to this RFI for planning potential future acquisitions and is seeking pertinent marketplace data to obtain quality services and products economically, and to efficiently and lawfully establish potential vendor source files and listings. BARDA will not award any potential contracts under this notice. This is strictly for market research.
Please note that the deadline for a response is no later than February 15, 2020.
The request for information can be found at: https://bit.ly/2LSjOEc